Zurück zur Übersicht
| Cancer treatment reviews. 2014 Dec 16. pii: S0305-7372(14)00209-6. doi: 10.1016/j.ctrv.2014.12.004 |
| Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development. |
| Stahel R1, Bogaerts J2, Ciardiello F3, de Ruysscher D4, Dubsky P5, Ducreux M6, Finn S7, Laurent-Puig P8, Peters S9, Piccart M10, Smit E11, Sotiriou C12, Tejpar S13, Van Cutsem E14, Tabernero J15 |
 Author information
|
|
Abstract Despite intense efforts, the socioeconomic burden of cancer remains unacceptably high and treatment advances for many common cancers have been limited, suggesting a need for a new approach to drug development. One issue central to this lack of progress is the heterogeneity and genetic complexity of many tumours. This results in considerable variability in therapeutic response and requires knowledge of the molecular profile of the tumour to guide appropriate treatment selection for individual patients. While recent advances in the molecular characterisation of different cancer types have the potential to transform cancer treatment through precision medicine, such an approach presents a major economic challenge for drug development, since novel targeted agents may only be suitable for a small cohort of patients. Identifying the patients who would benefit from individual therapies and recruiting sufficient numbers of patients with particular cancer subtypes into clinical trials is challenging, and will require collaborative efforts from research groups and industry in order to accelerate progress. A number of molecular screening platforms have already been initiated across Europe, and it is hoped that these networks, along with future collaborations, will benefit not only patients but also society through cost reductions as a result of more efficient use of resources. This review discusses how current developments in translational oncology may be applied in clinical practice in the future, assesses current programmes for the molecular characterisation of cancer and describes possible collaborative approaches designed to maximise the benefits of translational science for patients with cancer. |
|
Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved. |
|
KEYWORDS: Collaborative networks, Drug development, Molecular screening platforms, Translational oncology |
|
Publikations ID: 25533737 Quelle: öffnen |
Author information
Schnellinfo
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
